Chemotherapy of canine leishmaniosis

Gad Baneth*, Susan E. Shaw

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

143 Scopus citations

Abstract

Visceral leishmaniosis is a widespread and potentially fatal disease of dogs and humans common in the Mediterranean region, the Middle East, and South America. Canine leishmaniosis is most frequently treated with the drugs meglumine antimoniate, allopurinol, amphotericin B, or a combination of meglumine antimoniate and allopurinol. Therapy with the currently used drugs often achieves temporary clinical improvement and changes in immunologic parameters with restoration of the ability to mount parasite-specific cell mediated responses and decrease in anti-leishmanial antibody titers. However, treatment usually does not prevent relapse of disease or eliminate parasite carriage. Due to the current lack of an ultimate and effective therapy for canine leishmaniosis, new drugs, delivery systems and treatment strategies are necessary to achieve a consistent parasitological cure in infected dogs.

Original languageAmerican English
Pages (from-to)315-324
Number of pages10
JournalVeterinary Parasitology
Volume106
Issue number4
DOIs
StatePublished - 2 Jul 2002

Keywords

  • Allopurinol
  • Aminosidine
  • Amphotericin B
  • Dog
  • Leishmania infantum
  • Meglumine antimoniate
  • Pentamidine

Fingerprint

Dive into the research topics of 'Chemotherapy of canine leishmaniosis'. Together they form a unique fingerprint.

Cite this